FindTrial
Sign In

Effect of nicotine patch in Cognitive function improvement in Parkinson's disease

Effect of nicotine patch in Cognitive function improvement in Parkinson's disease - Effect of nicotine patch in Cognitive function improvement

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000016664
Enrollment
20
Registered
2015-03-01
Start date
2015-03-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson&#39

Interventions

nicotine patch

Sponsors

Department of Clinical Pharmacology and Neurology Ehime University graduated School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: The patients who had a diagnosis of Parkinson's disease, had mild cognitive dysfunction pointed out for the first time. It was 23 points or more in HDS-R, and 25 points or less in Moca (Montreal Cognitive Assessment) for Japan.

Exclusion criteria

Exclusion criteria: They received donepezil, galanthamine, administration of rivastigmine within study initiation two weeks. There was a change of the dose direction for use to an antiparkinson agent and the centrally acting drug (anxiolytics, antidepressants, anticonvulsant) taking. There is a remarkable disability in heart and the lungs liver renal function. The chief physician think the patient is inappropriate.

Design outcomes

Primary

MeasureTime frame
score of the driving simulator—

Secondary

MeasureTime frame
Distribution ratio of alpha wave Trail Making Test—

Countries

Japan

Contacts

Public ContactNoriko Nishikawa

Ehime University graduated School of Medicine Clinical Pharmacology and Neurology

n-nishi@m.ehime-u.ac.jp089-960-5095

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026